AR000509A1 - Utilización de un antagonist de sustancia p para la preparación de una composición farmacéutica paratratar algunas enfermedades de la piel de origen neurogeno - Google Patents
Utilización de un antagonist de sustancia p para la preparación de una composición farmacéutica paratratar algunas enfermedades de la piel de origen neurogenoInfo
- Publication number
- AR000509A1 AR000509A1 AR33461095A AR33461095A AR000509A1 AR 000509 A1 AR000509 A1 AR 000509A1 AR 33461095 A AR33461095 A AR 33461095A AR 33461095 A AR33461095 A AR 33461095A AR 000509 A1 AR000509 A1 AR 000509A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- substance
- antagonist
- heterocycle
- pharmaceutical composition
- Prior art date
Links
- 230000001272 neurogenic effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003890 substance P antagonist Substances 0.000 title abstract 2
- 208000017520 skin disease Diseases 0.000 title 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- -1 nitrogenous heterocyclic compound Chemical class 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 abstract 1
- 206010037083 Prurigo Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001907 coumarones Chemical class 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 229910017464 nitrogen compound Inorganic materials 0.000 abstract 1
- 150000002830 nitrogen compounds Chemical class 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001823 pruritic effect Effects 0.000 abstract 1
- SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical compound NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 abstract 1
- 150000008584 quinuclidines Chemical class 0.000 abstract 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 abstract 1
- 150000003577 thiophenes Chemical class 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9415251A FR2728265A1 (fr) | 1994-12-19 | 1994-12-19 | Utilisation d'un antagoniste de substance p dans une composition pharmaceutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR000509A1 true AR000509A1 (es) | 1997-07-10 |
Family
ID=9469929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR33461095A AR000509A1 (es) | 1994-12-19 | 1995-12-14 | Utilización de un antagonist de sustancia p para la preparación de una composición farmacéutica paratratar algunas enfermedades de la piel de origen neurogeno |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US5679360A (enExample) |
| EP (1) | EP0717997B1 (enExample) |
| JP (1) | JPH08208506A (enExample) |
| AR (1) | AR000509A1 (enExample) |
| AT (1) | ATE204177T1 (enExample) |
| BR (1) | BR9505382A (enExample) |
| CA (1) | CA2165520C (enExample) |
| DE (1) | DE69522188T2 (enExample) |
| ES (1) | ES2160680T3 (enExample) |
| FR (1) | FR2728265A1 (enExample) |
| HU (1) | HU218921B (enExample) |
| MX (1) | MX9505181A (enExample) |
| PL (1) | PL311916A1 (enExample) |
| RU (1) | RU2146519C1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6203803B1 (en) * | 1994-12-14 | 2001-03-20 | Societe L'oreal S.A. | Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained |
| FR2719474B1 (fr) * | 1994-05-05 | 1996-05-31 | Oreal | Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue. |
| FR2732221B1 (fr) * | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
| FR2738742B1 (fr) * | 1995-09-19 | 1997-11-14 | Oreal | Utilisation d'au moins une eau thermale de vichy en tant qu'antagoniste de substance p |
| FR2742054B1 (fr) * | 1995-12-06 | 1998-01-09 | Synthelabo | Compositions pharmaceutiques contenant un agent anti-inflammatoire et des ceramides vegetales |
| US7135191B2 (en) * | 1997-09-04 | 2006-11-14 | Zsolt Istvan Hertelendy | Urogenital or anorectal transmucosal vaccine delivery system |
| FR2768624B1 (fr) | 1997-09-25 | 1999-11-12 | Oreal | Utilisation d'un inhibiteur d'acides amines excitateurs dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue |
| US6214318B1 (en) | 1997-10-02 | 2001-04-10 | Oms Holdings Llc | Aerosol ointment compositions for topical use |
| DE19902530C1 (de) * | 1999-01-22 | 2000-05-25 | Goldwell Gmbh | Verwendung eines Mittels zum Behandeln von menschlichen Haaren |
| DE19902529A1 (de) * | 1999-01-22 | 2000-08-03 | Goldwell Gmbh | Haarbehandlungsmittel |
| EP1295599A1 (en) * | 2001-09-21 | 2003-03-26 | Boehringer Ingelheim International GmbH | Method for the treatment of prevention of atopic dermatitis |
| KR20090071581A (ko) | 2006-10-16 | 2009-07-01 | 라이온 가부시키가이샤 | Ｎｋ１ 수용체 앤태고니스트 조성물 |
| SG183878A1 (en) * | 2010-03-19 | 2012-10-30 | Oxygen Biotherapeutics Inc | Perfluorocarbon eye cream formulations |
| RU2443439C2 (ru) * | 2010-05-05 | 2012-02-27 | Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") | Способ лечения красного плоского лишая |
| WO2012044963A2 (en) * | 2010-10-01 | 2012-04-05 | Oxygen Biotherapeutics, Inc. | Perfluorocarbons for use in treating pruritus |
| SG11201501867UA (en) | 2012-10-11 | 2015-04-29 | Nerre Therapeutics Ltd | Novel uses |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US20170290774A1 (en) * | 2014-07-24 | 2017-10-12 | Plus Vitech, S.L. | Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3888976A (en) * | 1972-09-21 | 1975-06-10 | William P Mlkvy | Zinc and strontium ion containing effervescent mouthwash tablet |
| US3772431A (en) * | 1972-09-21 | 1973-11-13 | W Mlkvy | Effervescent mouthwash tablet |
| US4477439A (en) * | 1981-04-13 | 1984-10-16 | Walter J. Monacelli | Treatment of irritated and excoriated areas around the stoma of ostomy patients |
| WO1983001252A1 (en) * | 1981-10-09 | 1983-04-14 | Hakanson, Rolf | A drug based on a substance p antagonist |
| US4837026A (en) * | 1985-10-03 | 1989-06-06 | Rajakhyaksha Vithal J | Transdermal and systemic preparation and method |
| DE3584837D1 (de) * | 1985-10-08 | 1992-01-16 | Psori Med Ag | Salzmischung zur behandlung der schuppenflechte (psoriasis) und anderer hautkrankheiten. |
| US4986981A (en) * | 1986-07-07 | 1991-01-22 | Den Mat Corporation | Toothpaste having low abrasion |
| US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| SE8701372L (sv) * | 1987-04-02 | 1988-10-03 | Boliden Ab | Foerfarande och medel foer konservering av hoe |
| DE3929411A1 (de) * | 1988-09-22 | 1990-03-29 | Siegfried Natterer | Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung |
| CA2014201A1 (en) * | 1989-04-26 | 1990-10-26 | Albemarle Corporation | Solid non-hygroscopic trialkylamine oxides |
| US5202130A (en) * | 1989-08-31 | 1993-04-13 | The Johns Hopkins University | Suppression of eczematous dermatitis by calcium transport inhibition |
| EP0515681A4 (en) * | 1990-02-15 | 1993-12-29 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compound |
| JPH06509332A (ja) * | 1991-07-05 | 1994-10-20 | メルク シヤープ エンド ドーム リミテツド | 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用 |
| ATE133658T1 (de) * | 1991-07-10 | 1996-02-15 | Merck Sharp & Dohme | Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung |
| US5527808A (en) * | 1991-09-26 | 1996-06-18 | Pfizer Inc. | Fused tricyclic nitrogen containing heterocycles |
| DK0613458T3 (da) * | 1991-11-12 | 1998-02-09 | Pfizer | Acykliske ethylendiaminderivater som substans P receptorantagonister |
| GB9201179D0 (en) * | 1992-01-21 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
| JPH05339240A (ja) * | 1992-06-04 | 1993-12-21 | Yamanouchi Pharmaceut Co Ltd | テトラヒドロイソキノリンアミド誘導体 |
| DE9211006U1 (de) * | 1992-08-17 | 1993-12-16 | Kao Corporation GmbH, 40472 Düsseldorf | Mittel zur Haarbehandlung |
| JPH06199892A (ja) * | 1992-09-14 | 1994-07-19 | Takeda Chem Ind Ltd | Ｔａｎ−１６６６関連化合物 |
| GB9222486D0 (en) * | 1992-10-26 | 1992-12-09 | Merck Sharp & Dohme | Therapeutic agents |
| US5716625A (en) * | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
-
1994
- 1994-12-19 FR FR9415251A patent/FR2728265A1/fr active Granted
-
1995
- 1995-11-15 DE DE69522188T patent/DE69522188T2/de not_active Revoked
- 1995-11-15 AT AT95402551T patent/ATE204177T1/de active
- 1995-11-15 ES ES95402551T patent/ES2160680T3/es not_active Expired - Lifetime
- 1995-11-15 EP EP95402551A patent/EP0717997B1/fr not_active Revoked
- 1995-12-08 BR BR9505382A patent/BR9505382A/pt active Search and Examination
- 1995-12-11 MX MX9505181A patent/MX9505181A/es not_active IP Right Cessation
- 1995-12-14 AR AR33461095A patent/AR000509A1/es unknown
- 1995-12-18 JP JP7329298A patent/JPH08208506A/ja active Pending
- 1995-12-18 PL PL95311916A patent/PL311916A1/xx unknown
- 1995-12-18 CA CA002165520A patent/CA2165520C/fr not_active Expired - Fee Related
- 1995-12-18 RU RU95121103A patent/RU2146519C1/ru active
- 1995-12-18 HU HU9503624A patent/HU218921B/hu not_active IP Right Cessation
- 1995-12-19 US US08/574,653 patent/US5679360A/en not_active Expired - Fee Related
-
1997
- 1997-09-02 US US08/921,524 patent/US20020068072A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX9505181A (es) | 1997-02-28 |
| RU2146519C1 (ru) | 2000-03-20 |
| FR2728265A1 (fr) | 1996-06-21 |
| FR2728265B1 (enExample) | 1997-02-07 |
| CA2165520C (fr) | 2002-12-17 |
| JPH08208506A (ja) | 1996-08-13 |
| ATE204177T1 (de) | 2001-09-15 |
| HU218921B (hu) | 2000-12-28 |
| DE69522188D1 (de) | 2001-09-20 |
| ES2160680T3 (es) | 2001-11-16 |
| US5679360A (en) | 1997-10-21 |
| HUT74746A (en) | 1997-02-28 |
| CA2165520A1 (fr) | 1996-06-20 |
| EP0717997A1 (fr) | 1996-06-26 |
| HU9503624D0 (en) | 1996-02-28 |
| PL311916A1 (en) | 1996-06-24 |
| US20020068072A1 (en) | 2002-06-06 |
| EP0717997B1 (fr) | 2001-08-16 |
| BR9505382A (pt) | 1997-10-28 |
| DE69522188T2 (de) | 2001-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR000509A1 (es) | Utilización de un antagonist de sustancia p para la preparación de una composición farmacéutica paratratar algunas enfermedades de la piel de origen neurogeno | |
| AR062931A2 (es) | Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos | |
| UA41316C2 (uk) | Трициклічні похідні піролу і фармацевтичний препарат | |
| AR003938A1 (es) | Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos. | |
| MX9304359A (es) | Derivados de rapamicina. | |
| ES2161697T3 (es) | Peptidos agonistas de amilina y usos de los mismos. | |
| KR940001900A (ko) | 환상 유착 억제제 | |
| ES2161291T3 (es) | N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa. | |
| ECSP941122A (es) | Derivados de 5-arilindoles | |
| BR0009830A (pt) | Composições para cuidados com a pele contendo uma combinação de substâncias ativas para cuidados com a pele | |
| DK0725782T3 (da) | A1-adenosin-receptor-agonister og antiagonister | |
| ES2180530T3 (es) | Sulfonamidas de tiofeno utiles como inhibidores de anhidrasa carbonica. | |
| ECSP003682A (es) | Compuestos para el tratamiento de la isquemia | |
| FR2714378B1 (fr) | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. | |
| BRPI0416752B8 (pt) | composição farmacêutica, uso de um ou mais compostos, e, compostos | |
| BR0015605A (pt) | Composição e uso | |
| AR003427A1 (es) | Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas. | |
| ES2098921T3 (es) | Composiciones de cetoconazol de uso topico. | |
| ES2157314T3 (es) | Derivados triciclicos y su uso en productos farmaceuticos. | |
| FI941457A0 (fi) | Verihiutaleglyproteiini IIb/IIIa:n inhibiittoreina käyttökelpoisia syklisiä yhdisteitä | |
| CO5050328A1 (es) | Sistema solvente para la mejor penetracion de compuestos farmaceuticos | |
| RU94044534A (ru) | Амино-производные тиазола, способы их получения и содержащие их фармацевтические композиции | |
| AR007021A1 (es) | Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos | |
| ES2092646T3 (es) | Metanoantracenos como antagonistas de dopamina. | |
| AR000357A1 (es) | Utilización de un antagonista de sustancia p para la preparación de una composición farmacéutica de aplicación topica para tratar las manchas rojas cutaneas de origen neurogeno y especialmente la rosacea y el eritema pudico |